CompletedNot applicableNCT00004330
Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks
Studying Congenital erythropoietic porphyria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Center for Research Resources (NCRR)
- Principal Investigator
- Karl E AndersonUniversity of Texas
- Intervention
- luteinizing hormone-releasing factor(drug)
- Eligibility
- 18-55 years · FEMALE
- Timeline
- 1987
Study locations (1)
- University of Texas Medical Branch, Galveston, Texas, United States
Collaborators
University of Texas
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00004330 on ClinicalTrials.govOther trials for Congenital erythropoietic porphyria
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07567131Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)Portal Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT07024316A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEPAtlas Molecular Pharma